Cell Therapy for Diabetes Digital Consortium

Description

Diabetes is a chronic disorder with a huge unmet medical need, currently treatments aim to manage symptoms however these are expensive and time consuming for patients and healthcare systems, resulting in huge cost burdens and poor quality of life.

The Cell Therapy for Diabetes Digital Consortium will enable you to harness the clinical to commercial development of diabetes cell therapies through ensuring the engraftment of cells to host site, preventing immune activation and clearance and achieving scalable manufacturing to change patients’ lives.

Through the shared learnings and experiences of the fields brightest minds we will aim to bring you a platform to discuss the biggest obstacles to accelerating to market cell therapies for diabetes.

We gather the global leaders in diabetes, stem cell, autoimmune and beta cell replacement therapies as we improve the delivery, quality and scalability of cell therapies to transform the clinical to commercial development of diabetes cell therapies for patients in need.

Learn about the latest innovations in gene editing and engineering technologies alongside how to overcome the nitty gritty in process and analytical development. Join us for series of digital working groups to delve into the key challenges in this space and identify tangible solutions to takeaway.

At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of cell therapies for diabetes.

Home

August 26 / September 16 / October 7, 2020
9am – 1pm EST | 6am – 10am PST

Contact:
[email protected]

URL:
Brochure: https://go.evvnt.com/665737-2?pid=1175

Speakers: Yanick Fanton, Lab Director, Beta-Cell NV, Jason Fontenot, Senior Vice President, Cell Therapy, Sangamo Therapeutics, Mathias Svahn, Chief Executive Officer, Next Cell Pharma, William Rust, CEO and President, Seraxis, Matthias von Herrath, Vice President and Senior Medical Officer, Global Chief Medical Officer, Novo Nordisk, Kuldeep Singh Neote, VP, External Innovation, Eli Lilly